Mease PJ, Gladman DD, Papp KA, et al. Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics. J Am Acad Dermatol. 2013;69(5):729–35.

Article  PubMed  Google Scholar 

Coates LC, Soriano ER, Corp N, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol. 2022;18(8):465–79.

Article  PubMed  PubMed Central  Google Scholar 

Mahmood F, Coates LC, Helliwell PS. Current concepts and unmet needs in psoriatic arthritis. Clin Rheumatol. 2018;37(2):297–305.

Article  PubMed  Google Scholar 

Gossec L, Baraliakos X, Kerschbaumer A, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020;79(6):700–12.

Article  PubMed  Google Scholar 

Reis J, Vender R, Torres T. Bimekizumab: the first dual inhibitor of interleukin (IL)-17A and IL-17F for the treatment of psoriatic disease and ankylosing spondylitis. BioDrugs. 2019;33(4):391–9.

Article  PubMed  Google Scholar 

Costa L, Perricone C, Chimenti MS, et al. Switching between biological treatments in psoriatic arthritis: a review of the evidence. Drugs R D. 2017;17(4):509–22.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Adams R, Maroof A, Baker T, et al. Bimekizumab, a novel humanized IgG1 antibody that neutralizes both IL-17A and IL-17F. Front Immunol. 2020;11:1894.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Glatt S, Baeten D, Baker T, et al. Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation. Ann Rheum Dis. 2018;77(4):523–32.

Article  CAS  PubMed  Google Scholar 

Cole S, Manghera A, Burns L, et al. Differential regulation of IL-17A and IL-17F via STAT5 contributes to psoriatic disease. J Allergy Clin Immunol. 2023;152(3):783–98.

Article  CAS  PubMed  Google Scholar 

UCB Pharma S.A. Bimzelx (bimekizumab) 160 mg solution for injection in pre-filled pen or syringe: EU summary of product characteristics. 2023. https://www.ema.europa.eu/en/medicines/human/EPAR/bimzelx. Accessed 20 Mar 2024.

UCB Pharma Ltd. Bimzelx (bimekizumab) 160 mg solution for injection in pre-filled pen: UK summary of product characteristics. 2024. https://products.mhra.gov.uk/product/?product=BIMZELX%20160%20MG%20SOLUTION%20FOR%20INJECTION%20IN%20PRE-FILLED%20PEN. Accessed 20 Mar 2024.

UCB Pharma Ltd. Bimzelx (bimekizumab) 160 mg solution for injection in pre-filled syringe: UK summary of product characteristics. 2024. https://products.mhra.gov.uk/product/?product=BIMZELX%20160%20MG%20SOLUTION%20FOR%20INJECTION%20IN%20PRE-FILLED%20SYRINGE. Accessed 20 Mar 2024.

UCB Japan Co. Ltd. Bimzelx (bimekizumab): Japanese prescribing information. 2023. https://www.pmda.go.jp/PmdaSearch/iyakuDetail/820110_3999464G1020_1_03. Accessed 20 Mar 2024.

Rodríguez-Cerdeira C, González-Cespón JL, Martínez-Herrera E, et al. Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management. Ital J Dermatol Venerol. 2021;156(5):545–57.

PubMed  Google Scholar 

Oliver R, Krueger JG, Glatt S, et al. Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: efficacy, safety, pharmacokinetics, pharmacodynamics and transcriptomics from a phase IIa, randomized, double-blind multicentre study. Br J Dermatol. 2022;186(4):652–63.

Article  CAS  PubMed  Google Scholar 

McInnes IB, Asahina A, Coates LC, et al. Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL). Lancet. 2023;401(10370):25–37.

Article  CAS  PubMed  Google Scholar 

Merola JF, Landewé R, McInnes IB, et al. Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE). Lancet. 2023;401(10370):38–48.

Article  CAS  PubMed  Google Scholar 

Ritchlin CT, Kavanaugh A, Merola JF, et al. Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial. Lancet. 2020;395(10222):427–40.

Article  CAS  PubMed  Google Scholar 

Coates LC, Landewe R, McInnes IB, et al. Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL. RMD Open. 2024;10(1):e003855.

Article  PubMed  PubMed Central  Google Scholar 

Ritchlin CT, Coates LC, McInnes IB, et al. Bimekizumab treatment in biologic DMARD-naive patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study. Ann Rheum Dis. 2023;82(11):1404–14.

Article  CAS  PubMed  Google Scholar 

Merola J, Mease P, Deodhar A, et al. Bimekizumab impact on core Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) domains for patients with psoriatic arthritis: 52-week results from four phase 3 studies [abstract no. 1433]. Arthritis Rheumatol. 2023;75(Suppl 9).

McInnes I, Mease P, Tanaka Y, et al. Bimekizumab efficacy and safety in biologic DMARD-naïve patients with psoriatic arthritis was consistent with or without methotrexate: 52-week results from the phase 3 active‑reference study BE OPTIMAL [abstract no. POS1537 plus poster]. Ann Rheum Dis. 2023;82(Suppl 1):1133–4.

Gottlieb AB, Asahina A, Merola JF, et al. Bimekizumab improves joint measures in patients with active psoriatic arthritis and moderate or severe psoriasis: pooled 16-week results from phase 3 randomized, placebo-controlled studies BE OPTIMAL and BE COMPLETE [abstract no. 43024]. J Am Acad Dermatol. 2023;89(3 Suppl):AB128.

Tillett W, Merola J, Tanaka Y, et al. Bimekizumab maintained efficacy responses through 52 weeks in biologic disease-modifying antirheumatic drug-naive patients with psoriatic arthritis who were responders at week 16: results from BE OPTIMAL, a phase 3, active-reference study [abstract no. POS1534 plus poster]. Ann Rheum Dis. 2023;82(Suppl 1):1130–1.

Coates LC, McInnes IB, Merola JF, et al. Safety and efficacy of bimekizumab in patients with active psoriatic arthritis: three-year results from a phase IIb randomized controlled trial and its open-label extension study. Arthritis Rheumatol. 2022;74(12):1959–70.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sandal M. EULAR PsA recommendations update emphasizes safety, nonmusculoskeletal manifestations. 2023. https://www.medscape.com/viewarticle/993015?form=fpf. Accessed 20 Mar 2024.

Tanaka Y, Shaw S. Bimekizumab for the treatment of psoriatic arthritis. Expert Rev Clin Immunol. 2024;20(2):155–68.

Article  CAS  PubMed  Google Scholar 

Reich K, Warren RB, Lebwohl M, et al. Bimekizumab versus secukinumab in plaque psoriasis. N Engl J Med. 2021;385(2):142–52.

Article  CAS  PubMed  Google Scholar 

Warren RB, Blauvelt A, Bagel J, et al. Bimekizumab versus adalimumab in plaque psoriasis. N Engl J Med. 2021;385(2):130–41.

Article  CAS  PubMed  Google Scholar 

Reich K, Papp KA, Blauvelt A, et al. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial. Lancet. 2021;397(10273):487–98.

Article  CAS  PubMed  Google Scholar 

Mease PJ, Gladman DD, Merola JF, et al. Comparative efficacy and safety of bimekizumab in psoriatic arthritis: a systematic literature review and network meta-analysis. Rheumatology (Oxford). 2024. https://doi.org/10.1093/rheumatology/kead705.

Article  PubMed  Google Scholar 

Eli Lilly and Company (Ireland) Ltd. Taltz (ixekizumab): summary of product characteristics. 2023. https://www.ema.europa.eu/en/medicines/human/EPAR/taltz. Accessed 20 Mar 2024.

Novartis Europharm Ltd. Cosentyx (secukinumab): summary of product characteristics. 2023. https://www.ema.europa.eu/en/medicines/human/EPAR/cosentyx. Accessed 20 Mar 2024.